Moreover, functional studies suggest that CDK12-mediated cell cycle and metabolic vulnerabilities and the CDK12-induced neoantigens load might be promising candidates/biomarkers for targeted CDK12-specific cancer therapy (Table 1). This evidence concerns the gene CDK12 and cancer.